Answers are grounded in this paper and cite their sources.
• A “cryptic” pentaketide ansamycin gene cluster was activated. • Seven novel pentaketide ansamycins were isolated from Streptomyces . • Compounds 5 and 6 were active against Xanthomonas oryzae and Staphylococcus aureus . • CYP450 enzyme Tpm16 modulates the bioactivity of pathway intermediates. Although ansamycins are clinically important macrolactams, their pentaketide subset exhibits limited biological activities. Genome mining of rhizosphere-derived Streptomyces sp. LR53 uncovered a cryptic pentaketide ansamycin gene cluster ( tpm ). Activation via 3-amino-5-hydroxybenzoic acid (AHBA) feeding, promoter replacement, and deletion of the cytochrome P450 (CYP450) gene tpm16 enabled the discovery of seven novel metabolites, tropansamycins A–G ( 1 – 7 ), establishing the seventh distinct pentaketide ansamycin scaffold. Notably, congeners 5 and 6 , predominantly accumulated in the Δtpm16 mutant, exhibited potent activity against gram-negative pathogenic bacterium Xanthomonas oryzae and gram-positive bacterium Staphylococcus aureus , with MICs ranging from 2 to 8 μg/mL and were toxic to the producer strain cultivated on LB agar medium. This reveals that the CYP450 enzyme Tpm16 functions as a modification enzyme modulating the bioactivity profile of pathway intermediates. These findings not only expand the structural diversity of ansamycins but also highlight the potential of these pathogen-active ansamycins as promising leads.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: